TR200200165T2 - Substituted imidazothiazoles as antidepressants - Google Patents

Substituted imidazothiazoles as antidepressants

Info

Publication number
TR200200165T2
TR200200165T2 TR2002/00165T TR200200165T TR200200165T2 TR 200200165 T2 TR200200165 T2 TR 200200165T2 TR 2002/00165 T TR2002/00165 T TR 2002/00165T TR 200200165 T TR200200165 T TR 200200165T TR 200200165 T2 TR200200165 T2 TR 200200165T2
Authority
TR
Turkey
Prior art keywords
disorders
treatment
cerebral ischemia
eating
neurological
Prior art date
Application number
TR2002/00165T
Other languages
Turkish (tr)
Inventor
Andrew Brough Paul
Henstock Vincent
Paul Watts John
Original Assignee
Knoll Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Gmbh filed Critical Knoll Gmbh
Publication of TR200200165T2 publication Critical patent/TR200200165T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Formül I e sahip bilesikler ve bunlarin farmasötik açidan kabul edilebilir tuzlari (burada: A,S veya O dur; R1, H, halo, bir C1-3alkil grubu veya bir C1-3 alkiltio grubudur;R2, H ve flordur; ve R3, metil, etil veya izopropildir),depresyon, asiri endise, psikozlar (örnegin sizofreni), yavas gelisen diskinezi,asiri sismanlik, ilaç bagimliligi, ilaç suistimali, algilama bozukluklari,Alzheimer hastaligi, beyinsel iskemi, obsesif-kompalsif davranis, panik nöbetleri, sosyal fobiler, bulimiya,anoreksiya,aburcubur yeme içme gibi yeme bozukluklari, insüline bagimli olmayan sekerli diyabet, hiperglisemi, hiperlipidemi ve stresin tedavisinde ve nöbetler,epilepsi gibi nörolojik bozukluklar ve/veya felç, beyin travmasi, beyinsel iskemi, bas yaralanmalari ve kanamalari gibi nörolojik hasar olusan durumlarin tedavisi ve/veya önlemesi için yararlidirlar.Compounds of Formula I and their pharmaceutically acceptable salts (wherein: A is S or O; R1 is H, halo, a C1-3alkyl group or a C1-3 alkylthio group; R2 is H and fluorine; and R3 is methyl, ethyl or isopropyl), depression, extreme anxiety, psychosis (eg schizophrenia), slowly developing dyskinesia, excessive dysfunction, drug addiction, drug abuse, perception disorders, Alzheimer's disease, cerebral ischemia, obsessive-compulsive behavior, panic attacks, social phobias in the treatment of eating disorders such as bulimia, anorexia, eating junk food, non-insulin dependent diabetes mellitus, hyperglycemia, hyperlipidemia and stress, and neurological disorders such as seizures, epilepsy, and / or neurological damage such as stroke, brain trauma, cerebral ischemia, headache and bleeding. they are useful for the treatment and / or prevention of conditions.

TR2002/00165T 1999-05-21 2000-05-11 Substituted imidazothiazoles as antidepressants TR200200165T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9911881.2A GB9911881D0 (en) 1999-05-21 1999-05-21 Therapeutic agents

Publications (1)

Publication Number Publication Date
TR200200165T2 true TR200200165T2 (en) 2002-05-21

Family

ID=10853927

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00165T TR200200165T2 (en) 1999-05-21 2000-05-11 Substituted imidazothiazoles as antidepressants

Country Status (19)

Country Link
EP (1) EP1187836A1 (en)
JP (1) JP2003500409A (en)
KR (1) KR20020033625A (en)
CN (1) CN1361782A (en)
AU (1) AU4565200A (en)
BG (1) BG106228A (en)
BR (1) BR0010828A (en)
CA (1) CA2374915A1 (en)
CZ (1) CZ20014172A3 (en)
GB (1) GB9911881D0 (en)
HU (1) HUP0201543A2 (en)
IL (1) IL146541A0 (en)
MX (1) MXPA01011896A (en)
NO (1) NO20015668L (en)
PL (1) PL352288A1 (en)
SK (1) SK16842001A3 (en)
TR (1) TR200200165T2 (en)
WO (1) WO2000071548A1 (en)
ZA (1) ZA200110021B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0005789D0 (en) * 2000-03-11 2000-05-03 Knoll Ag Therapeutic agents
GB0023610D0 (en) * 2000-09-27 2000-11-08 Knoll Ag Therapeutic agents
CN100396667C (en) * 2006-02-20 2008-06-25 中国医学科学院医药生物技术研究所 Unsaturated five heterocycle compound for up-regulating bone formation protein BMP-2 expression activity
EP2247245B1 (en) 2008-02-18 2017-06-28 Covidien LP A device for deploying and attaching a patch to a biological tissue
US9034002B2 (en) 2008-02-18 2015-05-19 Covidien Lp Lock bar spring and clip for implant deployment device
US8758373B2 (en) 2008-02-18 2014-06-24 Covidien Lp Means and method for reversibly connecting a patch to a patch deployment device
US9833240B2 (en) 2008-02-18 2017-12-05 Covidien Lp Lock bar spring and clip for implant deployment device
US9393002B2 (en) 2008-02-18 2016-07-19 Covidien Lp Clip for implant deployment device
US9398944B2 (en) 2008-02-18 2016-07-26 Covidien Lp Lock bar spring and clip for implant deployment device
US8317808B2 (en) 2008-02-18 2012-11-27 Covidien Lp Device and method for rolling and inserting a prosthetic patch into a body cavity
US9044235B2 (en) 2008-02-18 2015-06-02 Covidien Lp Magnetic clip for implant deployment device
US9393093B2 (en) 2008-02-18 2016-07-19 Covidien Lp Clip for implant deployment device
US8808314B2 (en) 2008-02-18 2014-08-19 Covidien Lp Device and method for deploying and attaching an implant to a biological tissue
US9301826B2 (en) 2008-02-18 2016-04-05 Covidien Lp Lock bar spring and clip for implant deployment device
CA2730547C (en) 2008-10-20 2013-08-06 Polytouch Medical Ltd. A device for attaching a patch to a biological tissue
WO2011021083A1 (en) 2009-08-17 2011-02-24 PolyTouch Medical, Inc. Articulating patch deployment device and method of use
EP2467066B1 (en) 2009-08-17 2019-03-27 Covidien LP Means for reversibly connecting an implant to a deployment device

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160768A (en) * 1976-12-29 1979-07-10 Diamond Shamrock Corporation Anti-inflammatory 3-benzofuranyl imidazothiazole
GB9513467D0 (en) * 1995-07-01 1995-09-06 Knoll Ag Therapeutic agents
GB9705428D0 (en) * 1997-03-15 1997-04-30 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
MXPA01011896A (en) 2004-03-19
CN1361782A (en) 2002-07-31
HUP0201543A2 (en) 2002-08-28
BG106228A (en) 2002-08-30
ZA200110021B (en) 2003-05-28
SK16842001A3 (en) 2002-04-04
IL146541A0 (en) 2002-07-25
JP2003500409A (en) 2003-01-07
CA2374915A1 (en) 2000-11-30
EP1187836A1 (en) 2002-03-20
CZ20014172A3 (en) 2002-04-17
WO2000071548A1 (en) 2000-11-30
NO20015668L (en) 2002-01-21
NO20015668D0 (en) 2001-11-20
KR20020033625A (en) 2002-05-07
GB9911881D0 (en) 1999-07-21
BR0010828A (en) 2002-06-11
PL352288A1 (en) 2003-08-11
AU4565200A (en) 2000-12-12

Similar Documents

Publication Publication Date Title
TR200200165T2 (en) Substituted imidazothiazoles as antidepressants
TR200200164T2 (en) Thiazolo derivatives and pharmaceutical reactions containing them
CA2401033A1 (en) 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
EA200800430A1 (en) SUBSTITUTED TETRAHYDRO-1H-PYRIDO [4.3, B] INDOLS AS AGONISTS AND ANTAGONISTS OF SEROTONIN RECEPTORS
BR0307351A (en) Compound, pharmaceutical composition, method for treating a p38 kinase activity-mediated or cytokine-mediated condition or condition produced by p38 kinase activity, use of a compound, and process for preparing a compound
NZ507763A (en) N-substituted aminotetralin sulphonamide derivatives useful as ligands for the neuropeptide Y Y5 receptor used in the treatment of obesity and other disorders
EP0945440A4 (en) Aminopyrazole derivatives
WO2005080345A3 (en) Imidazoline derivatives having cb1-antagonistic activity
WO2005021495A3 (en) Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
HK1068622A1 (en) Novel heteroaryl derivatives, their preparation and use
NO306509B1 (en) Pyrimidine derivatives, their use and pharmaceutical preparation
GR3021583T3 (en) Substituted oxime-ethers, process for their production and their use as pesticides
EP0945439A4 (en) Novel aminopyrazole derivatives
AU6517296A (en) Heterocyclylcarboxamide derivatives and their use as therapeutic agents
CA2449854A1 (en) Aminoacetonitrile compounds for controlling endoparasites
TR199701756T1 (en) Concentrated thiazole derivatives with 5-HT affinity receptors.
CO5690542A2 (en) METHOD FOR THE PRODUCTION OF ACIL-FENIL-UREA DERIVATIVES REPLACED BY ANIMO-CARBON AND THE USE OF THE SAME
KR960704878A (en) Optically active imidazolidinone derivative and process for producing the same
FI956230A0 (en) beta-aminovinyl ketones, method of preparation and their use in the preparation of beta-diketones
BR9714237A (en) Compounds, use of a compound, processes for treating depression, anxiety, psychosis, tardive dyskinesia, parkinson's disease, obesity, hypertension, tourette's syndrome, sexual dysfunction, drug addiction, drug abuse, cognitive illness, alzheimer's disease, senile dementia , obsessive compulsive behavior, panic attacks, social phobias, diseases and food anorexia, cardiovascular and cerebrovascular diseases, diabetes mellitus not dependent on insulin, hyperglycemia, constipation, arrhythmia, diseases of the neuroendocrine system, tension and spasticity in humans and for preparation of compounds, and pharmaceutical composition.
CA2155796A1 (en) 2,3-dihydro-1h-isoindole derivatives, a process for their preparation and their use as serotonin reuptake inhibitors
MXPA03000429A (en) Novel aniline derivatives.
WO2002062801A1 (en) Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, medicinal compositions, adenosine a3 receptor affinity agents, ocular tension lowering agents, preparations for preventing and treating glaucoma and method of lowering ocular tension
CA2168265A1 (en) Antidepressant
CA2451229A1 (en) Indole derivatives